anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is designed to evaluate efficacy and safety of pazopanib versus sunitinib for the treatment of Asian subjects with locally advanced and/or metastatic renal cell carcinoma (RCC) enrolled from selected Far-East Asian countries. The primary objective is to evaluate the primary endpoint progression free survival in the enrolled Asian subjects treated with pazopanib versus those treated with sunitinib. The secondary objectives are to evaluate the following secondary endpoints in each treatment arm: objective response rate, duration of response, time to response, overall survival and safety. Subjects will be randomized in a 1:1 ratio to receive either 800mg pazopanib to be administered once daily orally continuous dosing or 50mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment. Subjects are permitted to receive supportive care throughout the study including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoietin, or bisphosphonates, when appropriate. The study treatment will continue until subjects experience disease progression, unacceptable toxicity, withdraw consent, or death.
Abdominal aortic aneurysm (AAA) is a life-threatening degenerative vascular disease characterized by transmural aortic macrophage infiltration, elastin degradation, and reduction of smooth muscle cell content. AAAs occurs later in life and are especially prevalent in men over the age of 65. Patients typically remain asymptomatic until rupture, which is associated with high mortality. Currently, surgical repair is the only approach for AAA treatment, and there is no pharmacological intervention. Clinically, ultrasound and computed tomography measurement of aneurysm diameter represents the mainstay of management and the principal determinant of timing for elective surgical repair. However, this anatomy-based approach fails to provide useful information about the cellular and molecular processes associated with aneurysm expansion and rupture. Therefore, developing translatable molecular biomarkers, specifically expressed by aneurysms, is necessary to determine associated status and progression, capture the risk of rupture, and deliver personalized treatment.
Chinook salmon (Oncorhynchus tshawytscha) farmed in New Zealand are known to develop abnormal spinal curvature late in seawater production. Its cause is presently unknown, but there is evidence to suggest a neuromuscular pathology. Using magnetic resonance imaging (MRI), we evaluated the relationship between soft tissue pathology and spinal curvature in farmed Chinook salmon. Regions of interest (ROIs) presenting as pathologic MRI signal hyper-intensity were identified from scans of 24 harvest-sized individuals: 13 with radiographically-detectable spinal curvature and 11 without. ROIs were excised from individuals using anatomical landmarks as reference points and histologically analysed. Pathologic MRI signal was observed more frequently in individuals with radiographic curvature (92%, n = 12) than those without (18%, n = 2), was localized to the peri-vertebral connective tissues and musculature, and presented as three forms: inflammation, fibrosis, or both. These pathologies are consistent with a chronic inflammatory process, such as that observed during recovery from a soft tissue injury, and suggest spinal curvature in farmed Chinook salmon may be associated with damage to and/or compromised integrity of the peri-vertebral soft tissues. Future research to ascertain the contributing factors is required.
Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
PCT No. PCT/AU89/00402 Sec. 371 Date Mar. 15, 1991 Sec. 102(e) Date Mar. 15, 1991 PCT Filed Sep. 18, 1989 PCT Pub. No. WO90/03162 PCT Pub. Date Apr. 5, 1990.An oral hygiene system includes a probe for use as a clinical measuring instrument or gauge. The probe is adapted for assessing the degree of inflamation of various animal tissues. One embodiment of the probe is useful for examination of periodontal tissues, particularly the determination of pocket depths and the degree of gingivitis. The probe has a needle member affixed orthogonally to one end of its head, and the other end of the head mounts in a handle. Between the two ends of the head there are thin resilient members adapted for transmitting an appropriate force to the tip of the needle during measurement of the depth of the pocket. Another needle member has upper and lower ends. At the lower end, there is a hemispherical tip having an angular bevel facing toward the upper end of the needle so as to form an equatorial rim about the tip. There are calibration marks extending from the tip of the needle.
This research is a randomized controlled study to evaluate the effect of Laughter yoga on the stress levels of infertility women. At the beginning of the study, necessary ethics committee permission and institutional permissions were obtained. Both of the researchers have a certificate of leadership in laughter yoga. As a result of the power analysis, it was determined that 80 women should be included in the study. Considering that there may be losses, it was decided to include 90 women in the study. By providing randomization, 90 women who met the sampling criteria and volunteered to participate in the study were divided into two groups as 45 experimental and 45 control. At the beginning of the study, the Infertility stress scale was applied to women in both groups to determine their stress levels. Afterwards, 8 sessions of laughter yoga were applied to the experimental group for 4 weeks, two sessions a week. No application was made to the control group. After 4 weeks, the Infertility stress scale was administered to the women in both groups to re-determine their stress levels.
A sugar-anchor polymer and methods of making and using the same to stabilize a lipid membrane. The sugar-anchor polymer includes a sugar covalently bound to a first anchor and a second anchor wherein the covalent bonds are selected from the group consisting essentially of an oxime bond, a hydrazone bond, an acylhydrazide bond, an aminothioacetal bond, an acetal bond, a thioacetal bond, a dithioacetal bond, a thioether bond and combinations thereof. The method includes reacting a sugar having at least two nucleophilic moieties with at least two anchors, each anchor having at least one electrophilic moiety, to form the polymer. Alternatively, the method includes reacting a sugar having at least two electrophilic moieties with at least two anchors, each anchor having at least one nucleophilic moiety, to form the polymer. The anchors may be lipids or peptides. The sugar-anchor polymers stabilize lipid membranes against serum proteins, dehydration, and cryopreservation.
Described is a system and method for controlling user interface (UI) properties with data. An application is separated into independent parts, a logic portion and a UI portion. The logic portion manipulates data values within the application. The UI portion is responsible for displaying UI properties. A  binding specification describes a relationship between the UI property and the data value. The binding specification is used by system level code to determine the manner in which it is notified when the data value undergoes a change and the manner in which it directs the UI portion to reflect the change in the UI property. The binding specification identifies a source data item, a path to the data value in the source data item, a target UI element, and the UI property on the target UI element. The binding may be specified using code or markup language.
PURPOSE:To remove organic substances contained in active carbon, to improve removing capacity for P, and to enable suitability for blood circulation by using an adsorbent prepd. from active carbon added with MgO-TiO2 compound having a specified compound ratio. CONSTITUTION:Alkoxides of Mg and Ti are mixed and solubilized in aq. soln. of an acid such as HNO3, etc. After dipping active carbon in the soln., the adsorbate is hydrolyzed with alkali such as NH3, etc., to obtain a precursor of the adsorbent, and an adsorbent of this invention is obtd. by calcining the precursor at 300-700 deg.C. The adsorbent comprises active carbon contg. an MgO- TiO2 compound adsorbed thereto, and preferred proportion of MgO/TiO2 expressed in terms of molar ratio is 99.99/0.01-80/20, and preferred amt. of the MgO/TiO2 compound adsorbed to the active carbon is 1-10wt.%. Suitable active carbon is spherical active carbon having 0.1-1mm mean particle size and 500-2,000m<2>/g specific surface area, etc.
This is a prospective, multicenter, observational investigator-initiated clinical study. The subjects were adults (18 years of age and older) diagnosed with relapsed/refractory diffuse large B-cell lymphoma who will begin cR2 therapy at the time of enrollment. Patients were required to complete a visit every 4 weeks, lasting 24 weeks from the first dosing of the study protocol. The first visit was considered an enrollment visit. The specific dosage of cR2 will be determined according to the standard clinical practice of the treating physician. Participation in the study did not affect treatment decisions. Patients who could not continue with the cR2 regimen would terminate the visit early and then withdraw from the study. According to the data collected from the experiment, the safety and effectiveness of the research scheme were analyzed.
A method of clustering or grouping objects that are similar to each other. The data set contains a set of quantitative values for each subject, each quantitative value representing a respective clinical or pathological characteristic of the subject. Principal component analysis, PCA, is performed on the data set. The loading of one of the first two principal components identified by the PCA is used to generate a corresponding data set of weighting values. These weighting values are used to weight or modify each set of quantitative values in the data set. A clustering algorithm is performed on the weighted object data set. The process may be iterated until a user-defined stop condition is met.
Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a \> 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
Myelosuppression was dose related and dose limiting. It consisted mainly of leukopenia and, to a lesser extent, thrombocytopenia. A WBC count <3000/μL is expected in 50% of the patients treated with ifosfamide single agent at doses of 1.2 g/m 2 per day for 5 consecutive days. At this dose level, thrombocytopenia (platelets <100,000/μL) occurred in about 20% of the patients. At higher dosages, leukopenia was almost universal, and at total dosages of 10 to 12 g/m 2/cycle, one half of the patients had a WBC count below 1000/μL and 8% of patients had platelet counts less than 50,000/μL. Myelosuppression was usually reversible and treatment can be given every 3 to 4 weeks. When ifosfamide is used in combination with other myelosuppressive agents, adjustments in dosing may be necessary. Patients who experience severe myelosuppression are potentially at increased risk for infection. Anemia has been reported as part of postmarketing surveillance.
The development of brain metastases hallmarks disease progression in 20-40% of melanoma patients and is a serious obstacle to therapy. Understanding the processes involved in the development and maintenance of melanoma brain metastases (MBM) is critical for the discovery of novel therapeutic strategies. Here, we generated transcriptome and methylome profiles of MBM showing high or low abundance of infiltrated Iba1high tumor-associated microglia and macrophages (TAMs). Our survey identified potential prognostic markers of favorable disease course and response to immune checkpoint inhibitor (ICi) therapy, among them APBB1IP and the interferon-responsive gene ITGB7. In MBM with high ITGB7/APBB1IP levels, the accumulation of TAMs correlated significantly with the immune score. Signature-based deconvolution of MBM via single sample GSEA revealed enrichment of interferon-response and immune signatures and revealed inflammation, stress and MET receptor signaling. MET receptor phosphorylation/activation maybe elicited by inflammatory processes in brain metastatic melanoma cells via stroma cell-released HGF. We found phospho-METY1234/1235 in a subset of MBM and observed a marked response of brain metastasis-derived cell lines (BMCs) that lacked druggable BRAF mutations or developed resistance to BRAF inhibitors (BRAFi) in vivo to MET inhibitors PHA-665752 and ARQ197 (tivantinib). In summary, the activation of MET receptor in brain colonizing melanoma cells by stromal cell-released HGF may promote tumor self-maintenance and expansion and might counteract ICi therapy. Therefore, therapeutic targeting of MET possibly serves as a promising strategy to control intracranial progressive disease and improve patient survival.
One of the subgroups of breast cancer is known as triple negative breast cancer. This subgroup is difficult to treat, and patients have a short life span. It is an extremely fatal disease. Although surgery, radiotherapy, and chemotherapy are the main treatment methods in cancer treatment, chemotherapy is essential in the treatment of this disease. However, new chemotherapeutic agents are needed because the treatment is still not successful with existing chemotherapeutics. Therefore, new chemotherapeutics need to be synthesized. In this study, the synthesis and characterization of a new naphthoquinone-based therapeutic agent were performed for the first time in the world. The synthesis steps, the results of the structural characterization studies, and the experimental findings on how it leads to cell death are clearly described. As a result, it was concluded that the compound of the patent showed a cytotoxic effect by killing the cells with apoptosis, and also it is a new compound with an anticancer effect since it showed an anti-migratory effect, and the patent application was decided.
PROBLEM TO BE SOLVED: To safely produce the subject powder without using an organic solvent, at a low cost, having improved releasing properties of a hardly soluble material and useful for medicines, cosmetics, etc., by burying the hardly soluble material in starch and thereafter applying a dynamic stress thereon. SOLUTION: The objective powder holding a hardly soluble material in modified porous starch granules is obtained by burying a hardly soluble material (e.g. indomethacin) in a porous starch obtained by acting an enzyme having raw starch- degrading ability (e.g. amylase) on the starch (e.g. corn starch), and thereafter applying a dynamic stress thereon. The application of the dynamic stress is performed by using not only a ball mill, a hammer mill and a vibrating mill but also a jet mil, etc.  In the case of the ball mil, the powder holding the hardly soluble material in the modified starch is obtained by changing the structure of the porous starch into an α-structure while enclosing the hardly soluble material therein by impact because the porous starch has viscoelasticity, and in the case of the jet mill, the powder of the modified starch with the attached hardly soluble material is obtained by finely milling the porous starch carrying the hardly soluble material together with the hardly soluble material.
Macroautophagy (hereafter called autophagy) is an essential physiological process of degradation of organelles and long-lived proteins. The discovery of autosis, a Na+/K+-ATPase (ATP1)-dependent type of autophagic cell death with specific morphological and biochemical features, has strongly contributed to the acceptance of a pro-death role of autophagy. However, the occurrence and relevance of autosis in neurons has never been clearly investigated, whereas we previously provided evidence that autophagy mechanisms could be involved in neuronal death in different in vitro and in vivo rodent models of hypoxia-ischemia (HI) and that morphological features of autosis were observed in dying neurons following rat perinatal cerebral HI. In the present study, we demonstrated that neuronal autosis could occur in primary cortical neurons using two different stimulations enhancing autophagy flux and neuronal death: a neurotoxic concentration of Tat-BECN1 (an autophagy-inducing peptide) and a hypoxic/excitotoxic stimulus (mimicking neuronal death induced by cerebral HI). Both stimulations induce autophagic neuronal death (dependent on canonical autophagic genes and independent on apoptotic, necroptotic or ferroptotic pathways) with all morphological and biochemical (ATP1a-dependent) features of autosis. However, we demonstrated that autosis is not dependent on the ubiquitous subunit ATP1a1 in neurons, as in dividing cell types, but on the neuronal specific ATP1a3 subunit. We also provided evidence that, in different in vitro and in vivo models where autosis is induced, ATP1a3-BECN1 interaction is increased and prevented by cardiac glycosides treatment. Interestingly, an increase in ATP1a3-BECN1 interaction is also detected in dying neurons in the autoptic brains of human newborns with severe hypoxic-ischemic encephalopathy (HIE). Altogether, these results suggest that ATP1a3-BECN1-dependent autosis could play an important role in neuronal death in HI conditions, paving the way for the development of new neuroprotective strategies in hypoxic-ischemic conditions including in severe case of human HIE.
Studies have shown that these patients have muscle weakness and delayed activity of trunk muscles, significant loss of trunk position sense, insufficient pressure control center while sitting, decreased trunk performance, and trunk asymmetry during walking. It has been reported that trunk function with balance and walking ability in stroke patients is a useful determinant of daily life activities, balance and walking ability. Balance disorders may be the result of changes in the sensory and integrative aspects of motor control. In the subacute phase, more than 80% of the subjects who have had stroke for the first time have an imbalance in their balance. After a stroke, upper motor neuron damage can cause unconditioned. This results in physical inactivity and decreased cardiorespiratory fitness. Respiratory muscle weakness and changes in thoraco-abdominal motion may be associated with a decrease in tidal volume and lower exercise tolerance.
<P>PROBLEM TO BE SOLVED: To provide a crosslinked polymer composition achieving an inherent adhesion between surfaces and achieving enhancement of a structure; and the use thereof.  <P>SOLUTION: This crosslinked polymer composition contains a first synthetic polymer having a plurality of nucleophilic groups which is bonded to a second synthetic polymer having a plurality of electrophilic groups through a covalent bond. The first synthetic polymer is preferably a synthetic polypeptide or polyethylene glycol modified to have a plurality of nucleophilic groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer and either contains two or more electrophilic groups or is converted into a derivative having two or more electrophilic groups. This composition can contain further other components. Further, there are also disclosed such methods by using this crosslinked polymer composition as a method for achieving an adhesion between a first surface and a second surface, a method for achieving enhancement of a structure, a method for preventing a formation of a surgical adhesion and a method for coating the surface of a synthetic implant.  <P>COPYRIGHT: (C)2007,JPO&INPIT
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine namely to taumatology and neurology, and can be used in conservative treatment of patients with large joint osteoarthritis at early stages. For this purpose in muscles of affected limb trigger points are determined with further putting on them ointment application consisting of equal parts of chondroxide and diclofenac-AKOS for 5-7 minutes. Also hypertonic compresses containing 4-layer gauze bandage soaked with hypertonic sodium chloride solution with temperature 37 degrees is applied for 40 minutes. Daily during three days at exactly set time manual influence on trigger points is performed. Intervals between sessions are 24 hours. Then curse of hyperbaric oxygenation is carried out, which consists of 8 sessions 50 minutes each with operating pressure in isopressure mode 1.3 at. Before and after course of treatment amplitude of electromyogramme of muscles belonging to affected joint is registered, data are presented in form of petal diagram by which area of irregular quadrangle is determined, which is proportional to total bioelectric activity of tested muscles. If area increases at more than 10% treatment effect is estimated as positive, in other case medical influence is corrected changing character and component composition of influence. ^ EFFECT: complex influence on all links of said disease pathogenesis with possibility of timely treatment correction due to changes registered on electromyogramme. ^ 2 cl, 2 ex, 4 dwg
Participants will receive the SOC + a daily 20-30 minute electro-acupuncture treatment from the time of randomization until the return of bowel function. The first treatment will be provided within 48 hours after the diagnosis of postoperative ileus. Participants will receive acupuncture every day until normal bowel movement function returns.
Technological innovation has advanced the efficacy of spine surgery for patients; however, these advances do not consistently translate into clinical effectiveness. Some patients who undergo spine surgery experience continued chronic back pain and other complications that were not present before the procedure. Defects in healthcare value, such as the lack of clinical benefit from spine surgery, are, unfortunately, common, and the US healthcare system spends $1.4 trillion annually on value defects. In this article, we examine how avoidable complications, postacute healthcare use, revision surgeries, and readmissions among spine surgery patients contribute to $67 million of wasteful spending on value defects. Furthermore, we estimate that almost $27 million of these costs could be recuperated simply by redirecting patients to facilities referred to as centers of excellence. In total, quality improvement efforts are costly to implement but may only cost about $36 million to fully correct the $67 million in finances misappropriated to value defects. The objectives of this article are to present an approach to eliminate defects in spine surgery, including a center-of-excellence framework for eliminating defects specific to this group of procedures.
Patients assigned to the furosemide infusion group will receive furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al. (2007) and the SPARK study protocol (Bagshaw et al. 2010). Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline reaching a concentration of 4 mg/mL. All medication and placebo bags will have no identifiers that show what type of drug is being administered, for blinding purposes. Medication and placebo bags will have randomly generated study identifier numbers. The protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the manufacturer.